• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Pimavanserin Improves Negative Symptoms of Schizophrenia
RESEARCH UPDATE

Pimavanserin Improves Negative Symptoms of Schizophrenia

January 1, 2023
Brian Miller, MD, PhD, MPH
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

REVIEW OF: Bugarski-Kirola D et al, Lancet Psychiatry 2022;9(1):46–58

STUDY TYPE: Randomized placebo-controlled trial

Negative symptoms of schizophrenia—including apathy, asociality, and blunted affect—predict disease burden and are difficult to treat. We lack FDA-approved therapies, and we don’t know whether antipsychotics with novel mechanisms of action have efficacy for negative symptoms. Pimavanserin (Nuplazid) is a novel antipsychotic approved for psychotic symptoms in Parkinson’s disease. Rather than antagonizing the dopamine D2 receptor, pimavanserin appears to work by blocking the 5-HT2A receptor, where it is both an antagonist and an inverse agonist (as an antagonist, it blocks the receptor; as an inverse agonist, it binds to the receptor and induces the opposite effects as an agonist). An earlier trial found benefits for pimavanserin augmentation in major depression (Fava M et al, J Clin Psychiatry 2019;80(6):19m12928), and the current study is the first to test pimavanserin augmentation for negative symptoms of schizophrenia.

This was a randomized, double-blind, placebo-controlled trial of pimavanserin as an adjunct to ongoing antipsychotic medication, in 403 stable adult outpatients ages 18–55 (mean 38) with schizophrenia and predominant negative symptoms in North America and Europe (specifically, patients scored at least 20 on the negative symptom domain of the Positive and Negative Syndrome Scale [PANSS]). Patients were treated with either pimavanserin (starting dose 20 mg daily, dose range 10–34 mg daily) or placebo, in addition to their current antipsychotic, for 26 weeks. The primary outcome was change in the Negative Symptom Assessment (NSA-16) from baseline to week 26. The secondary endpoint was change in the Personal and Social Performance (PSP) scale, which assesses functioning in four areas: socially useful activities; personal and social relationships; self-care; and disturbing and aggressive behaviors. A total of 86% of subjects completed the trial.

After 26 weeks, the pimavanserin group showed a significantly greater reduction in negative symptoms versus placebo (-10.4 vs -8.5 points on the NSA-16), corresponding to a small effect size (0.21), but no change in PSP score (difference 0.0). In post-hoc analyses, the effect size for the NSA-16 was greater in patients who received the 34 mg dose of pimavanserin (0.34), as well as in men, patients from Europe, and patients with chronic negative symptoms (lasting longer than five years). Adverse effects were similar between study groups (35%–40%), most commonly headache and somnolence, and were typically mild. Pimavanserin was associated with a modest but statistically significant increase in the QT interval as compared to placebo (4.5 vs 0.0 ms). There were no clinically relevant effects of pimavanserin on vital signs, weight, glucose, or lipids in this six-month study.

Potential limitations included the flexible dosing schedule, as only 54% of patients were increased to a 34 mg pimavanserin dose. The study participants were stable outpatients with chronic schizophrenia who primarily suffered from negative symptoms, which may limit the generalizability of the study findings. We also don’t know whether response to pimavanserin will vary depending on the antipsychotic it is combined with.

CARLAT TAKE

Adjunctive pimavanserin may improve negative symptoms in patients with stable, chronic schizophrenia. However, the overall effect is small, and the price of the medication is high ($4,000 monthly).

General Psychiatry Research Update
KEYWORDS adjunct-treatment negative symptoms pimavanserin schizophrenia
    Brian Miller, MD, PhD, MPH

    Does Childhood Maltreatment Reduce Response to Antidepressant Treatment?

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Viibryd Goes Generic, But Is It Worth Prescribing?
    20 Years of The Carlat Report
    Aripiprazole-Related Psychotic Exacerbations
    Should We Use Two Antidepressants to Treat Unipolar Depression?
    DBT Skills May Reduce Polypharmacy in Borderline Personality Disorder
    Pimavanserin Improves Negative Symptoms of Schizophrenia
    CME Post-Test, Psychiatric Education, TCPR, January 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.